Market Place
Sourcing Support
Nuvation Bio to Present at 7th Annual Evercore ISI HealthCONx Conf
26 Nov 2024 //
BUSINESSWIRE
Nuvation Bio to Present at the Jefferies London Health Conference
12 Nov 2024 //
BUSINESSWIRE
Nuvation Bio Reports Q3 2024 Results & Business Update
06 Nov 2024 //
BUSINESSWIRE
Nuvation Bio Appoints Philippe Sauvage As Chief Financial Officer
07 Oct 2024 //
BUSINESSWIRE
Nuvation Bio to head to FDA with pooled ROS1-positive lung cancer data
14 Sep 2024 //
ENDPNTS
Nuvation Bio to Present at the Cantor Global Healthcare Conference
09 Sep 2024 //
BUSINESSWIRE
Nuvation Bio Reports Q2 2024 Results And Business Update
05 Aug 2024 //
BUSINESSWIRE
Nuvation halts BET inhibitor program after considering phase 1 solid tumor data
05 Aug 2024 //
FIERCE BIOTECH
Nuvation Bio Updates On ROS1 Inhibitor Taletrectinib
23 Jul 2024 //
BUSINESSWIRE
Nuvation`s Taletrectinib ROS1 Inhibitor Data Published In JCO, At ASCO
01 Jun 2024 //
BUSINESSWIRE
Nuvation Bio to Present at the Jefferies Global Healthcare Conference
29 May 2024 //
BUSINESSWIRE
Nuvation Bio shares pivotal China data for cancer drug from AnHeart buyout
23 May 2024 //
ENDPTS
Nuvation Bio Reports Q1 2024 Financial Results, Business Update
14 May 2024 //
BUSINESSWIRE
Nuvation Presents Taletrectinib ROS1 Inhibitor Data at ASCO
24 Apr 2024 //
BUSINESSWIRE
Nuvation Bio Completes Acquisition of AnHeart Therapeutics
10 Apr 2024 //
BUSINESSWIRE
Nuvation Bio Announces Appointment of Colleen Sjogren as Chief CO
28 Mar 2024 //
BUSINESSWIRE
Nuvation Bio nears commercial stage with AnHeart buy
26 Mar 2024 //
PHARMAPHORUM
Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction
25 Mar 2024 //
BUSINESSWIRE
Nuvation Bio Doses First Patient in Phase 1/2 Study of NUV-1511
14 Mar 2024 //
BUSINESSWIRE
Nuvation Bio Reports Fourth Quarter and Full Year 2023 Financial Results
29 Feb 2024 //
BUSINESSWIRE
Nuvation Bio Announces FDA Clearance of Investigational NDA for NUV-1511
08 Jan 2024 //
BUSINESSWIRE
Nuvation Announces Appointment of Dr. Robert Mashal to its Board of Directors
08 Jan 2024 //
BUSINESSWIRE
Nuvation Bio Announces Departure of Chief Financial Officer
13 Nov 2023 //
BUSINESSWIRE
Nuvation Bio Reports Third Quarter 2023 Financial Results
02 Nov 2023 //
BUSINESSWIRE
Nuvation Bio Reports Second Quarter 2023 Financial Results
03 Aug 2023 //
BUSINESSWIRE
Nuvation Bio Announces Formation of Oncology-Focused Scientific Advisory Board
01 Jun 2023 //
BUSINESSWIRE
Nuvation Bio Reports 1Q FYR 2023 and Provides Business Update
04 May 2023 //
BUSINESSWIRE
Nuvation Bio Reports Fourth Quarter and Full Year 2022 Financial Results
15 Mar 2023 //
BUSINESSWIRE
Nuvation Bio Doses First Patient in Phase 1b Combination Study of NUV-868
19 Dec 2022 //
BUSINESSWIRE
Nuvation Bio Reports 3Q FYR and Provides Business Update
03 Nov 2022 //
BUSINESSWIRE
Nuvation Bio Reports Second Quarter 2022 Financial Results
04 Aug 2022 //
BUSINESSWIRE
Nuvation drops tumor asset and reduces staff by a third
02 Aug 2022 //
FIERCEBIOTECH
Nuvation Bio Announces Discontinuation of NUV-422 Clinical Development Program
01 Aug 2022 //
BUSINESSWIRE
Nuvation Bio Appoints David Liu, M.D., Ph.D., as CMO and Kerry Wentworth as CRO
18 Jul 2022 //
BUSINESSWIRE
Nuvation`s new solid tumor focus hits snag on FDA hold
28 Jun 2022 //
FIERCEBIOTECH
Moneybags Nuvation deprioritizes 2 solid tumor prospects
11 May 2022 //
FIERCEBIOTECH
Nuvation Bio Reports First Quarter 2022 Financial Results
09 May 2022 //
BUSINESSWIRE
US FDA clears Nuvation Bio’s application for solid tumour therapy
21 Jan 2022 //
PHARMACEUTICAL-TECHNOLOGY
Nuvation Bio Provides Corporate Update and Highlights Key 2022 Milestones
10 Jan 2022 //
PRNEWSWIRE
Nuvation Bio Receives FDA FTD for NUV-422 in High-Grade Gliomas
15 Dec 2021 //
PRNEWSWIRE
FDA Clears iNDA for Nuvation Bio`s NUV-422 for Prostate Cancer
11 Dec 2021 //
PRNEWSWIRE
Nuvation Bio Reports Q3 2021 Financial Results and Provides Business Update
10 Nov 2021 //
PRNEWSWIRE
Nuvation Bio Reports Second Quarter 2021 Financial Results
12 Aug 2021 //
PRNEWSWIRE
Nuvation Bio Reports First Quarter 2021 Financial Results and Provides
17 May 2021 //
PRNEWSWIRE
Nuvation Bio Granted Orphan Drug Designation for NUV-422
11 Mar 2021 //
PRNEWSWIRE
Nuvation Bio Granted Orphan Drug Designation for NUV-422
10 Mar 2021 //
PRNEWSWIRE
Nuvation Bio Closes Transaction with Panacea, Debuts as Publicly Traded
10 Feb 2021 //
PRNEWSWIRE
Ex-Medivation team nets $500M to take their new cancer drugmaker to Wall Street
21 Oct 2020 //
BIOPHARMADIVE
Nuvation Bio Announces FDA Acceptance of (IND) Application for NUV-422
12 Oct 2020 //
PRNEWSWIRE
